Davenport & CO LLC Taysha Gene Therapies, Inc. Transaction History

Davenport & CO LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	SELL	$2.47 - $6.77 $1,235 - $3,385	-500 Reduced 1.81%	27,170 $101,000
Q4 2021 Feb 10, 2022	SELL	$11.43 - $19.2 $629,793 - $1.06 Million	-55,100 Reduced 66.57%	27,670 $322,000
Q3 2021 Oct 14, 2021	BUY	$15.82 - $21.57 $1.09 Million - $1.49 Million	69,020 Added 501.96%	82,770 $1.54 Million
Q2 2021 Jul 28, 2021	SELL	$19.29 - $26.38 $123,456 - $168,832	-6,400 Reduced 31.76%	13,750 $292,000
Q1 2021 Apr 28, 2021	BUY	$20.3 - $31.75 $409,045 - $639,762	20,150 New	20,150 $409,000

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.